L4 - Overview of Neoplasia History and Classification Flashcards

1
Q

Tumour

A

Swelling. Commonly used to describe neoplasia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Neoplasm

A

A new and abnormal growth of tissue in a part of the body, especially as a characteristic of cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hyperplasia

A
  • Increase in number of cells.

* Benign, usually not neoplastic, reversible.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hypertrophy

A
  • Increase in size of cells
  • No increase in number of cells
  • May be physiological or pathological
  • Not neoplastic
  • e.g. skeletal muscle, cardiac muscle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Metaplasia

A
  • Change from the normal cell type, to another cell type, in response to stimuli, usually noxious.
  • Not neoplastic, but if the stimulus persists, may progress to neoplasia in some circumstances.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Dysplasia

A
  • Abnormal cell growth.
  • May be neoplastic and pre-malignant.
  • May regress
  • e.g. Colon adenoma.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Eponymous tumours

A
  • Hodgkin lymphoma
  • Burkitt Lymphoma
  • Ewing sarcoma
  • Kaposi sarcoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Other neoplasms

A

• Melanoma, Lymphoma, Neuroblastoma, Nephroblastoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Differentiation

A
  • The extent to which tumour cells recapitulate normal cells in structure and/or function.
  • Benign tumours are generally well differentiated, and are only recognised as tumours because of formation of an abnormal mass, or abnormalities in hormones or genetics
  • Malignant tumours are classified as well, moderately, poorly differentiated, or undifferentiated/anaplastic.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pleomorphism

A
  • Variation in size and shape of the cell or the nucleus (or both).
  • Pleomorphism increases with loss of differentiation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Nuclear atypia of neoplastic cells

A
  • Hyperchromasia
  • Change in nuclear cytoplasmic ratio
  • Mitotic activity
  • Loss of polarity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hyperchromasia

A

Dark nuclei due to increased amount of chromatin, in same volume of nucleus. (Increased “blueness” on H+ E stained sections).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Change in nuclear cytoplasmic ratio

A

Usually increased, ie the nucleus increases in size in relation to the cytoplasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Mitotic activity

A

Usually more helpful in malignant tumours. Particularly if bizarre mitoses are present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Loss of polarity

A

Some cells shows polarity of the nucleus (eg glandular epithelial cells). In neoplasia, the cells may lose this polarity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Benign Neoplasms

A
  • Slow growing
  • Locally confined
  • Cause symptoms by mass effect, e.g. compression of adjacent structures, or production of hormones with distant effects.
  • May be asymptomatic until very large in some sites.
  • May cause significant problems, even when very small (eg pituitary adenomas)
  • Cured by surgical excision.
  • Unlikely to cause death, except where the mass effects or hormone production affect vital functions. (eg benign tumours in brain stem, functional pituitary adenomas).
17
Q

Malignant Neoplasms

A
  • Tumour is not confined
  • Capable of invasion of adjacent organs/structures
  • Capable of distant metastasis (spread)
  • Only curable if completely excised before spread and/or sensitive to appropriate treatment.
  • Cytologically more atypical than benign tumours
  • May be more mitotically active than benign tumours, especially atypical mitoses.
18
Q

Spread of malignant tumours

A
  • Direct invasion
  • Lymphatic invasion (to lymph nodes)
  • Vascular invasion (to other organs in the vascular pathway, eg colonic adenocarcinoma spreading to the liver)
  • Transcoelomic spread (eg gastric carcinoma spreading through the peritoneal cavity to the ovary “Krukenberg”tumour
19
Q

Grade

A

A measure of how aggressively a tumour behaves

• Grade generally corresponds with differentiation and mitotic activity

20
Q

Stage

A

How far the tumour has advanced at the time of diagnosis

  • AJCC (TNM staging)
  • Features of the Tumour (Size, extent of local invasion)
  • Nodal involvement
  • Metastasis
21
Q

Tests for Lipoma vs Liposarcoma

A
  • FISH for specific translocations
  • Immunohistochemistry can be used as a surrogate (MDM2, CDK4)
  • Cytogenetics
22
Q

Lymphoma tests

A
  • PCR; IgH gene rearrangements, T Cell receptor gene rearrangements to prove clonality.
  • FISH, for specific translocations eg t14:18, in follicular lymphoma (over-expression of bcl2, which inhibits apoptosis)
23
Q

Lung carcinomas and melanoma metastases

A
  • Knowledge of the molecular basis of carcinogenesis can provide prognostic and therapeutic information
  • Lung adenocarcinomas may be caused by EGFR mutations. There are targeted therapies available which provided therapeutic benefit if the mutation is present (gefitinib). (Although the drugs don’t work if Kras mutations also present.)
  • Similar targeted therapy is available for melanomas that harbour BRAF mutations (eg vemurafinib).
24
Q

Breast Carcinoma

A
  • Tissue microarray (“Gene Chips”) were used in the reclassification of breast carcinoma into types based on the genetics of the tumours, rather than just the histologic appearance.
  • Microarray technology also provides the basis for a move towards “personalised” cancer therapy, in which each cancer can be typed based on a large number of known mutations and matched against currently available targeted therapies.